Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07277257 · ClinicalTrials.gov registry record · Phase 4
Evaluating a New Therapy for Dry Eye in Patients With Sjögren's Syndrome
A Phase 4 study of Sjogren Syndrome With Keratoconjunctivitis, sponsored by Center For Sight.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT07277257: Recruiting Phase 4 study of Sjogren Syndrome With Keratoconjunctivitis, sponsored by Center For Sight.
NCT07277257 is a Phase 4 study of Sjogren Syndrome With Keratoconjunctivitis that is actively recruiting participants, run by Center For Sight. The registered enrollment target is 35 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07277257, a Phase 4 study of Sjogren Syndrome With Keratoconjunctivitis, is actively recruiting participants, sponsored by Center For Sight.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the effect of TRYPTYR in patients with Sjögren's syndrome-related dry eye disease. The goal is to determine whether TRYPTYR can improve symptoms and signs of dry eye in this specific patient population.
Primary Outcome
Unanesthetized Schirmer's test will be measured prior to instillation and then again 3 minutes after instillation of the TRYPTYR. The difference between the 2 measurements will be compared.
Conditions Studied
Interventions
- DRUG TRYPTYR (Acoltremon ophthalmic solution 0.003%)
Study Locations (1)
Florida
- Center For Sight - Venice
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-12-02 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
What NCT07277257 shows while recruiting
NCT07277257 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Sjogren Syndrome With Keratoconjunctivitis appearing as the primary indexed condition, and to 1 intervention - of which TRYPTYR (Acoltremon ophthalmic solution 0.003%) is the first listed.
NCT07277257 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07277257 about?
NCT07277257 is a clinical study titled "Evaluating a New Therapy for Dry Eye in Patients With Sjögren's Syndrome". This study will evaluate the effect of TRYPTYR in patients with Sjögren's syndrome-related dry eye disease. The goal is to determine whether TRYPTYR can improve symptoms and signs of dry eye in this specific patient population.
What is the current status of trial NCT07277257?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2025-12-02. Estimated completion is 2026-12-31.
What conditions does trial NCT07277257 study?
This clinical trial studies the following conditions: Sjogren Syndrome With Keratoconjunctivitis.
What interventions are being tested in trial NCT07277257?
The interventions under investigation include: TRYPTYR (Acoltremon ophthalmic solution 0.003%) (DRUG).
Who is sponsoring clinical trial NCT07277257?
This trial is sponsored by Center For Sight, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07277257 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07277257's enrollment target sits among peer trials
35 1506th of 2000 higher than 482 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI